RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
62 hedge funds and large institutions have $45.1M invested in RVL Pharmaceuticals plc Ordinary Shares in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 17 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
10% more capital invested
Capital invested by funds: $41.1M → $45.1M (+$3.97M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 66 → 62 (-4)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DG Capital Management
New York
|
+$4.08M |
| 2 |
CCM
CAAS Capital Management
New York
|
+$2.69M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$2.46M |
| 4 |
Morgan Stanley
New York
|
+$1.4M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.04M |
| 2 |
EP
Eversept Partners
New York
|
-$532K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$332K |
| 4 |
JIC
Joel Isaacson & Co
New York
|
-$303K |
| 5 |
BlackRock
New York
|
-$274K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FDCDDQ
76
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$76.6K | -11,341 | Closed |
|
77
HSBC Holdings
London,
United Kingdom
| – | -$76K | -11,262 | Closed |
|
|
RA
78
Royce & Associates
New York
| – | -$34K | -5,012 | Closed |
|
|
PHK
79
Point72 Hong Kong
Hong Kong
| – | -$23K | -3,408 | Closed |
|
RVLP Hedge Fund Activity: Q3 2020 in Review
62 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q3 2020, worth a combined $45.1M — up 9.7% from $41.1M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of RVLP and 13 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 27 added.
The largest buyer was DG Capital Management, adding an estimated $4.08M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.04M sold.
- 62 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q3 2020, down from 66 in Q2 2020.
- Funds reported $45.1M of RVL Pharmaceuticals plc Ordinary Shares stock for Q3 2020, up 9.7% quarter-over-quarter.
- 13 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q3 2020 and 17 closed out, a net change of -4 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q3 2020 was DG Capital Management, an estimated $4.08M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q3 2020 was Acadian Asset Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q3 2020.